DI is informing some investors that they are working on a journal which will help support the agency applications. Other investors get told "refer to Oct 5th PR"
So that tells me we have not submitted an approval or are utilizing a rolling BLA.
Also wondering how a journal publication affects FDA approval. FDA should be making that decision independent of any publications.
Market Data 
Markets 
AI
